Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.

摘要: The impact of treatment on health-related quality life (HRQoL) is an important consideration in the adjuvant operable breast cancer. Here we report mature HRQoL outcomes from ATAC trial, comparing anastrozole with tamoxifen as primary therapy for postmenopausal women localized Patients completed Functional Assessment Cancer Therapy-Breast (FACT-B) questionnaire plus endocrine subscale (ES) at baseline, 3 and 6 months, every months thereafter. Baseline characteristics sub-protocol were well balanced between (n = 335) 347) groups analysis population. As previously published results 2 years, there was no statistically significant difference Trial Outcome Index FACT-B, endpoint study, treatments 5 years. There differences ES total scores. Consistent 2-year analysis, patient-reported side effects: diarrhea (anastrozole 3.1% vs. 1.3%), vaginal dryness (18.5% 9.1%), diminished libido (34.0% 26.1%), dyspareunia (17.3% 8.1%) significantly more frequent compared to tamoxifen. Dizziness (3.1% 5.4%) discharge (1.2% 5.2%) less In this, first over years initial aromatase inhibitor, conclude that had similar impacts HRQoL, which maintained or slightly improved during period both groups.